Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: A serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1438-1445

  Zhao, Ying Yong ^a   Cheng, Xian Long ^b   Cui, Ji Hong ^a   Yan, Xing Rong ^a   Wei, Feng ^b   Bai, Xu ^c   Lin, Rui Chao ^b  

^a NORTHWEST UNIVERSITY   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c Waters Technologies Shanghai Ltd   (China)

Author keywords

Chronic renal failure; Ergosta 4,6,8(14),22 tetraen 3 one; MassLynx i FIT algorithm; Metabonomics; Polyporus umbellatus; UPLC HSMS

Indexed keywords

ADENINE; ASPARTIC ACID; BIOLOGICAL MARKER; CREATININE; DOPAMINE; ERGOSTA 4,6,7(14),22 TETRAEN 3 ONE; LYSOPHOSPHATIDYLCHOLINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; STEROID; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CHEMOMETRIC ANALYSIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENERGY METABOLISM; HISTOPATHOLOGY; KIDNEY FIBROSIS; MALE; METABOLITE; MOLECULAR WEIGHT; NONHUMAN; OUTCOME ASSESSMENT; POLYPORUS UMBELLATUS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADENINE; ANIMALS; ASPARTIC ACID; CHOLESTENONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DOPAMINE; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; PHENYLALANINE; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

POLYPORUS UMBELLATUS; RATTUS;

EID: 84862625083     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.06.005     Document Type: Article

References (53)

1. Collins A.J., Kasiske B., Herzog C., et al. United States Renal Data System. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005, 45(1Suppl. 1):A5-A7.
2. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway. Kidney Int 2006, 70:1914-1919.
3. Yu H.T. Progression of chronic renal failure. Arch Intern Med 2003, 163:1417-1429.
4. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 2004, 43:9-17.
5. Coresh J., Astor B.C., Greene T. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: the third National Health and Nutrition Examination survey. Am J Kidney Dis 2003, 41:1-12.
6. Locatelli F., Del Vecchio L., Pozzoni P., Manzoni C. Nephrology: main advance in the last 40years. J Nephrol 2006, 19:6-11.
7. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006, 70:26-33.
8. Bensky D., Gamble A. Chinese herbal medicine materia medica 1993, Eastland Press, Seattle. Revised edition.
9. Zhao Y.Y., Zhao Y., Zhang Y.M., Lin R.C., Sun W.J. Qualitative and quantitative analysis of the diuretic component ergone in Polyporus umbellatus by HPLC with fluorescence detection and HPLC-APCI-MS/MS. Pharmazie 2009, 64:366-370.
10. Zhao Y.Y., Cheng X.L., Zhang Y.M., Zhao Y., Lin R.C., Sun W.J. Simultaneous determination of eight major steroids from Polyporus umbellatus by high-performance liquid chromatography coupled with mass spectrometry detections. Biomed Chromatogr 2010, 24:222-230.
11. Zhao Y.Y., Yang L.B., Wang M.M., et al. 1β-hydroxylfriedelin, a new natural pentacylic triterpene from the sclerotia of Polyporus umbellatus. J Chem Res 2009, 11:699-701.
12. Lee W.Y., Park Y., Ahn J.K., Park S.Y., Lee H.J. Cytotoxic activity of ergosta-4,6,8(14),22-tetraen-3-one from the sclerotia of Polyporus umbellatus. Bull Korean Chem Soc 2005, 26:1464-1466.
13. Yuan D., Mori J., Komatsu K.I., Makino T., Kano Y. An anti-aldosteronic diuretic component (drain dampness) in Polyporus sclerotium. Biol Pharm Bull 2004, 27:867-870.
14. Fujimoto H., Nakamura E., Okuyama E., Ishibashi M. Six immunosuppressive features from an ascomycete, Zopfiella longicaudata, found in a screening study monitored by immunomodulatory activity. Chem Pharm Bull 2004, 52:1005-1008.
15. Zhao Y.Y., Xie R.M., Chao X., Zhang Y.M., Lin R.C., Sun W.J. Bioactivity-directed isolation, identification of diuretic compounds from Polyporus umbellatus. J Ethnopharmacol 2009, 126:184-187.
16. Zhao Y.Y., Zhang L., Mao J.R., et al. Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. J Pharm Pharmacol 2011, 63:1581-1586.
17. Zhao Y.Y., Chao X., Zhang Y.M., Lin R.C., Sun W.J. Cytotoxic steroids from Polyporus umbellatus. Planta Med 2010, 76:1755-1758.
18. Zhao Y.Y., Shen X., Chao X., et al. Ergosta-4,6,8(14),22-tetraen-3-one induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. BBA-Gen Subj 2011, 1810:384-390.
19. Zhao Y.Y., Qin X.Y., Chen X.L., et al. Rapid resolution liquid chromatography-mass spectrometry and high-performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one. Anal Chim Acta 2010, 675:199-206.
20. Zhao Y.Y., Qin X.Y., Zhang Y.M., Lin R.C., Sun W.J., Li X.Y. Quantitative HPLC method and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one, a natural product with diuretic activity from Polyporus umbellatus. Biomed Chromatogr 2010, 24:1120-1124.
21. Zhao Y.Y., Cheng X.L., Zhang Y.M., Chao X., Lin R.C., Sun W.J. A fast and sensitive HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of ergone in rats. J Chromatogr B 2010, 878:29-33.
22. Elevated Energy data collection technique: determination and pharmacokinetics, tissue distribution and biliary excretion study of ergone in rat. J Sep Sci 2012, 10.1002/jssc.201200131.
23. Bailey W.J., Ulrich R. Molecular profiling approaches for identifying novel biomarkers. Expert Opin Drug Saf 2004, 3:137-151.
24. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 2006, 23:1075-1088.
25. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics in pharmaceutical R & D. FEBS J 2007, 274:1140-1151.
26. Robertson D.G., Reily M.D., Baker J.D. Metabonomics in pharmaceutical discovery and development. J Proteome Res 2007, 6:526-539.
27. Griffin J.L., Bollard M.E. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr Drug Metab 2004, 5:389-398.
28. Zhao Y.Y., Liu J., Cheng X.L., Bai X., Lin R.C. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin Chim Acta 2012, 413:642-649.
29. Yin P.Y., Zhao X.J., Li Q.R., Wang J.S., Li J.S., Xu G.W. Metabonomics study of intestinal fistulas based on ultra performance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J Proteome Res 2006, 5:2135-2143.
30. Fukui Y., Kato M., Inoue Y., Matsubara A., Itoh K. A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis. J Chromatogr B 2009, 877:3806-3812.
31. Lao Y.M., Jiang J.G., Yan L. Application of metabonomic analytical techniques in the modernization and toxicology research of traditional Chinese medicine. Br J Pharmacol 2009, 157:1128-1141.
32. Lan K., Jia W. An integrated metabolomics and pharmacokinetics strategy for multi-component drugs evaluation. Curr Drug Metab 2010, 11:105-114.
33. n. Bioanalysis 2012, 4:713-723.
34. Zhao Y.Y., Cheng X.L., Liu R., et al. Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography-atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry. J Chromatogr B 2011, 879:1945-1953.
35. Roux A., Lison D., Junot C., Heilier J.F. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin Biochem 2011, 44:119-135.
36. Zhao Y.Y., Cheng X.L., Wei F., et al. Serum metabonomics study of adenine-induced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 2012, 17:48-55.
37. Yang J., Zhao X.J., Liu X.L., et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B. J Proteome Res 2006, 5:554-561.
38. Yokozawa T., Zheng P.D., Oura H., Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986, 44:230-234.
39. Bancroft J.D., Cook H.C. Connective tissues. Manual of histological techniques and their diagnostic application 1994, 42-43. Churchill-Livingstone, New York.
40. Lopansri B.K., Anstey N.M., Stoddard G.J., et al. Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. Infect Immun 2006, 74:3355-3359.
41. Fernstrom J.D., Fernstrom M.H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 2007, 137:1539S-1547S.
42. Exton J.H. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1994, 1212:26-42.
43. Jia L.W., Chen J., Yin P.Y., Lu X., Xu G.W. Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 2008, 4:183-189.
44. Sutphen R., Xu Y., Wilbanks G.D., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:1185-1191.
45. Zhang F., Jia Z., Gao P., et al. Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 2009, 79:836-844.
46. Zhang J., Yan L., Chen W., et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009, 650:16-22.
47. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001, 70:281-312.
48. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
49. Fukui M., Nakamura T., Ebihara I. ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 1992, 41:1520-1527.
50. Lynch J.J., Ferro T.J., Blumenslock F.A. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 1990, 85:1991-1998.
51. Gillett M.-P.T., Obineche E.N., Lakhani M.S., et al. Levels of cholesteryl esters and other lipids in the plasma of patients with end-stage renal failure. Ann Saudi Med 2001, 21:283-286.
52. Duong C.Q., Bared S.M., Abu-Khader A., Buechler C., Schmitz A., Schmitz G. Expression of the lysophopholipid receptor family and investigation of lysophopholipid-mediated responses in human macrophages. Biochim Biophys Acta 2004, 1682:112-119.
53. Oestvang J., Johansen B. Phospholipase A2: a key regulator of inflammatory signaling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta 2006, 1761:1309-1316.